The synthesis of 5-methyl-2-thienylketopolymethylene oxyphenyl 4,5-dihydro-2-(alkyl)oxazoles was accomplished by the assembly of two synthones, namely 1-(5-methyl-2-thienyl)-7-hydroxy-1-heptanone (or 1-(5-methyl-2-thienyl)-5-chloro-1-pentanone) and 4-[4,5-dihydro(alkyl)oxazol-2-yl]phenol, in the presence of diethyl azodicarboxylate(DEAD)-triphenyl phosphine (or sodium iodide and anhydrous potassium carbonate). Eighteen new disoxaril analogues were synthesized by the above procedure and tested in vitro against several rhino and enteroviruses. With a few exceptions, all test derivatives were more potent than WIN 51711 when assayed against HRV-14, and as potent as WIN 51711 against HRV-2, but none of them inhibited the other 'HRV serotypes. Among the various derivatives, two compounds showed the same wide spectrum activity of WIN 51711 against several rhino, and enteroviruses, but were at least 10-fold less toxic.
Introduction
Disoxaril (WIN 51711, 1) ( Fig. 1 ) and its analogues are among the most potent inhibitors of human picornaviruses (Smith et al., 1986) . These compounds exert their antiviral activity by stabilizing the virion structure, thus inhibiting virion uncoating. Alternatively, they induce conformational changes which affect the putative viral receptor binding sites, thus preventing virion absorption to cell receptors (Fox et al., 1986; Pevear et al., 1989) .
In a study on homologues of disoxaril ( Fig. 1) , it has been shown that the introduction of alkyl substituents at position 4 of the oxazoline ring led to derivatives (2) which showed greater activity than 1 against several rhinovirus serotypes (Diana et al., 1988) . Among the 4-alkyloxazolines, the S enantiomer of 2a has been shown to be 10 times more effective than disoxaril in inhibiting human rhinovirus-14 . Compounds more effective than 1 were also obtained by introducing a series of substituents in the 2 position of the phenoxy moiety (Diana et al., 1987), More recently, some thienylketopolymethylene analogues of disoxaril, which showed potent anti-HRV activity in vitro, were synthesized. Structure Activity Relationship (SAR) studies on these compounds have shown that the structural features which correlate with the best biological profile are: a thiophene ring as heterocyclic terminus; a CI atom or a CH 3 group in the a-position of thiophene; a carbonyl group bound to the position 2 of thiophene; a tetramethylene chain connecting the carbonyl group to the phenoxy moiety; an oxazoline or an ethoxycarbonyl substituent on the phenoxy ring. In particular, compound 3 has shown in vitro a potency 10 times greater and a cytotoxicity at least 10 times lower than WIN 51711 (Massa et el., 1991 (Massa et el., , 1995 .
Therefore, in an attempt to improve the antirhinoviral activity of 3 by introducing an alkyl group in to the oxazoline ring, the alkyloxazolines represented by formulae 4 and 5 were synthesized (Fig. 2 ). In addition, compounds of formulae 6 and 7 were prepared and tested for antipicornavirus activity with the aim of exploring the influence of the chlorine atom at position 2 of the phenyl ring, and determining whether the oxazoline ring could be replaced by open chain substituents such as carbethoxy or ethyl Nacetylalaninate moieties. 
Results
Chemistry. Friedel-Crafts acylation ( Fig. 3 ) of 2-methylthiophene with pimelic anhydride (Hill et el., 1933) in the presence of aluminium trichloride afforded 7-(5-methyl-2thienyl)-7-oxoheptanoic acid 8, which was reduced with lithium aluminium hydride to the corresponding heptadiol 9. Selective oxidation of 9 with activated manganese dioxide gave 1-(5-methyl-2-thienyl)-7-hydroxy-1-heptanone 10, which was also obtained in very low yield by borane/tetrahydrofuran complex reduction of the ketoacid 8. Reaction of 10 with 4-(4,5-dihydro-2-oxazolyl)phenols lla-f, 12a (X = R = R 1 = R 2=H), 12b (X = CI, R = R 1 = R 2 = H) (Diana et el., 1985b (Diana et el., , 1987 and ethyl 4hydroxybenzoate (13) in the presence of diethyl azodicarboxylate (DEAD)-triphenylphosphine according to the Mitsunobu procedure (Mitsunobu, 1981) furnished the desired 1-(5-methyl-2-thienyl)-7-phenoxy-1-heptanones 5a-g, 6b, and 7a. No reaction occurred when N-acetyl-Ltyrosine ethyl ester (ATEE) monohydrate (14) was reacted with the Mitsunobu reagents. Therefore, to obtain 7e, the hydroxy alkylketone 10 was treated with triphenylphosphine and carbon tetrachloride with formation of the corresponding chloroderivative 15. Reaction of this compound with 14 in the presence of potassium carbonate and sodium iodide yielded 7e. 1-(S-Methyl-2-thienyl)-S-phe" noxy-1-pentanones 4a-f, 6a and 7b were obtained from chloroalkylketone 16 ( Fig. 4 ) by treatment with 4-(4,S-dihydro-2-oxazolyl)phenols 11a-f, 12b and ATEE monohydrate (14), respectively, according to previously described procedures (Massa et al., 1991 (Massa et al., , 1995 . 4-(4,S-Dihydro-4-(or 5)substituted-2-oxazolyl)phenols 11a-f were obtained by reaction of 4-hydroxybenzonitrile with the appropriate amino alcohols in the presence of catalytic amounts of zinc dichloride in refluxing chlorobenzene, according to the Witte and Seeliger procedure (Witte and Seeliger, 1974) as partially modified by Balm (Bolm et et., 1991) (Fig. S) .
Moreover, in order to make certain that no racemization had occurred during the zinc-catalyzed ring formation of 11e from (R)-2-amino-1-propanol (D-alaninol), derivative 11e was treated with (8)-1 O-camphorsulfonyl chloride, with formation of only one product, identified as the (R)-4-(4,S-dihydro-4-methyl-2-oxazolyl)phenol ester of (8)-10camphorsulfonic acid (17). Finally, the very convenient two-step procedure used to prepare 1-(S-methyl-2thienyl)-7-hydroxy-1-heptanone 10 was also employed to synthesize 1-(S-methyl-2-thienyl)-4-hydroxy-1-butanone 20 which, in previous studies (Massa et et., 1991 (Massa et et., , 1995 was prepared in low yield starting from known 4-(5-methyl-2-thienyl)-4-oxobutanoic acid 18 (McGhie et al., 1962) (Fig. 6) .
The chemical and physical data for these compounds is shown in Table 1a and brief analytical data is presented in Table 1b .
Virology. Compounds 4a-f, 5a-g, 6a,b and 7a-e were screened for anti-HRV activity in a tetrazolium-based colorimetric assay (MTT assay) using HeLa-Ohio cells. Tests were carried out against HRV-14 and HRV-2, which are representatives of the major and minor receptor groups (Colonno et al., 1986) other than members of the antiviral groups A and B (Andries et al., 1990) , respectively. The compounds active against one or both of these strains were further tested against the same additional 13 serotypes that had been chosen to test the activity of the [(oxazolyl)phenoxy alkyl]isoxazoles..In fact, all the above
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the broad spectrum activity of antirhinovirus compounds (Diana et al., 1989) . Therefore, ECsos and MICsos (i.e. compound concentrations that inhibit 80% of the serotypes tested) were the basis for the SAR considerations. Table 2 shows the cytotoxicity and the anti-HRV activity of the new compounds, together with those obtained with WIN 51711 and 3 as reference drugs. In in-vitro assays against HRV-14, various compoundS
ii Reagents: i. 11n·( or 12b,.NoI,KzC03' CH 3CN, reflux,ii. 14, NaI, KZC03' CH3CN, reflux. showed activities superior to those observed with the reference drug WIN 51711. The five-carbon chain derivatives 4a, 4e, 4d, 4e and the related seven-carbon chain counterparts Sa, 5e, 5d and 5e were the most potent, showing EC so values ranging between 0.26 and 0.81 J.lM. With the exception of 6a, 7b and 7e, the remaining derivatives (4b, 4f, 5b, Sf, 5g, 6b and 7a) showed EC so values (1.3-1.9 J.lM) very close to that of WIN 51711. However, none of the new derivatives were as potent as 3 (EC so =0.14 J.lM) (Massa et al., 1995) against this serotype. Moreover, when compared to 3, many of the new derivatives were also more cytotoxic.
As far as the anti-HRV-2 activity was concerned, the majority of the test derivatives were as active as the reference drugs, and the sole derivative 6b (EC so = 0.47 J.lM) appeared superior to both 3 (EC so = 1.3 J.lM) and WIN 51711 (EC so = 2.35 J.lM).
Interestingly, 6b and 7a were the only derivatives with a wide spectrum of anti-HRV activity, showing MIC so s (5.2 and 4.1 J.lM, respectively) comparable to that of WIN 51711. Also they were not cytotoxic for subconfluent HeLa monolayers (Table 2 ) and proliferating MT-4 lymphocytes (data not shown). Test compounds were also evaluated in vitro for their capability to prevent the cytopathogenicity induced in VERO cells by Poliovirus 1, 2, 3 and Coxsackie B-2 and B-5. As shown in Table 3 , none of the compounds were active against Polio 1 and Coxsackie B-5, whereas many of them inhibited Polio 2, 3 and Coxsackie B-2 at concentrations comparable to those active against sensitive rhinovirus serotypes.
Discussion
The analysis of SAR of the test compounds allows the following conclusions. As with homologues of disoxaril (Diana et al., 1987 (Diana et al., , 1988 , the introduction of alkyl groups at position 4 of the oxazoline ring improves both the anti-HRV-14 and anti-HRV-2 activity of derivatives 5 (which have six methylene groups in the ketomethylene chain connecting the thiophene ring to the 4-(oxazolin-2-yl)phenoxy moiety) while not influencing the activity of counterparts with four methylene groups (compound 4). As for WIN derivatives, S enantiomers are more active than R enantiomers.
The introduction of a second methyl group at position 4 of the oxazoline ring (4d, 5d) leads essentially to the same results, i.e. improvement of the activity of derivative 5 and worsening of that of derivatives 4. Unfortunately, the alkyl-substituted derivatives show neither broad spectrum anti rhinovirus activity nor favourable cytotoxicity profile.
The introduction of a CI atom at position 2 of the phenoxy ring again produces the best results in the hexamethylene derivatives. In this case the substitution leads to EC s';,
Compounds
Po1i0- a compound (6b) endowed with broad spectrum antirhinovirus activity and low cytotoxicity. Both properties are maintained when the oxazoline ring is substituted for a carbethoxy moiety (7a) (Diana et al., 1985a; Massa et al., 1991 Massa et al., , 1995 , demonstrating, in agreement with previous works, that 4,5-dihydro-2-oxazolyl and ethoxycarbonyl (but not carboxy) moieties can be exchanged without loss of activity. On the contrary, when open chain substituents such as ethyl-N-acetylalaninate are used, the activity is lost. (Table 1) , and biological studies (Tables 2 and 3) were dried in high vacuum over P 2 0 S for 20 h at temperatures ranging from 25 to 110°C, depending on the sample melting point. General procedure for the preparation of derivatives 5a-g,
Materials and Experimental Procedures: Chemistry

6b,7a
A solution of diethyl azodicarboxylate (DEAD) (0.54 mL, 3.4 mMol) in dry THF (20 mL) was added over a period of 10 min to a solution containing 10 (0.70 g, 3.1 mMol), the phenolic derivative 11a-f, 12a-b; or 13 (3.4 mMol), and triphenylphosphine (0.89 g, 3.4 mMol) in dry THF (80 mL). The mixture was stirred at room temperature until starting materials disappeared (TLC control). After removal of the solvent, the residue was partitioned between water (100 mL) and CHCl s (100 mL), and the aqueous phase was extracted three times with fresh CHCl s (50 mL). The combined organic layers were washed twice with 2N KOH (50 mL), then with brine (50 mL), dried and evaporated. The residue was purified by column chromatography to afford 5a-g, 6b or 7a. Illustrative spectroscopic data for 6b and 7a are given. (rn, 4H, CO(CH 2h(CH2MCH 2hO); 1.70-1.88 (m, 4H, OCH 2CH2 and COCH 2CH2); 2.53 (s, 3H, CH s); 2.80-2.88 (t, 2H, COCH 2); 3.97-4.03 (t, 2H, PhOCH 2); 4.29-4.39 (q, 2H, J = 6.9 Hz, CH 2CHs); 6.77-6.79 (d, 1H, H-4 thiophene ring); 6.86-6.91 (d, 2H, J = 8.8 Hz, H-3,5 benzene ring); 7.50-7.52 (d, 1H, H-3 thiophene ring); 7.95-8.00 (d, 2H, J = 8.8 Hz, H-2,6 benzene ring).
General procedure for the preparation of derivatives 4a-f,
6a,7b,c
To a stirred solution of oxoalkylchloride 15 or 16 (2.3 mMol) in dry acetonitrile (50 mL) sodium iodide (0.30 g, 1.8 mMol), anhydrous potassium carbonate (0.40 g, 2.8 mMol) and the proper phenolic derivative 11a-f, 12b or 14 (2.8 mMol) were added. The suspension was refluxed for 72 h, then filtered while still hot and the obtained solution evaporated. The residue was partitioned between AcOEt (100 mL) and water (100 mL) and the aqueous phase was extracted three times with fresh AcOEt (50 mL). The combined organic layers were washed successively with 5% aqueous NaOH (50 mL), 5% aqueous sodium thiosulfate (50 mL) and brine (50 mL). Evaporation of the solvent left a solid residue, which was chromatographed to give pure 4a-f, 6a or 7b,c.
General procedure for the preparation of derivatives 11a-f
Zinc chloride (0.15 g, 1.1 mMol) was melted under high vacuum and cooled to room temperature with a nitrogen stream. Then dry chlorobenzene (150 mL), 4-hydroxybenzonitrile (2.60 g, 22.2 mMol) and the proper amino alcohol (5.20 mL, 66.6 mMol) were added. The mixture was heated under reflux for 64-92 h, then the solvent was removed to give an oily residue, which was partitioned between AcOEt (50 mL) and water (50 mL).
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The aqueous phase was neutralized with 1N KOH and extracted with AcOEt (3x30 mL). The organic layers were combined, washed with brine (100 mL), dried and evaporated to furnish an oily residue which was purified by column chromatography.
7-0xo-7-(5-methyl-2-thienyl)heptanoic acid 8
A solution of pimelic anhydride (8.90 g, 62.4 mMol) and anhydrous aluminium chloride (8.30 g, 62.4 mMol) in 1,2dichloroethane (100 mL) was added dropwise to a stirred solution of 2-methylthiophene (6.10 g, 62.4 mMol) in 1,2-dichloroethane (100 mL). After stirring for 1.5 h, the mixture was treated with ice (200 g) and conc. HCI (20 mL) and the aqueous phase was extracted with 1,2-dichloroethane (2x50 mL). The organic layers were combined and extracted with 2N KOH (2x50 mL). The alkaline extracts were acidified with dil. HCI, extracted with CH 2CI 2 (3x50 mL) and the organic extracts were washed with brine (100 mL) and dried. Evaporation of solvent furnished 8 as a solid pure on TLC (Si0 2/AcOEt).
General procedure for the preparation of derivatives 9,19
A suspension of oxoalkanoic acid 8 or 18 (18.3 mMol) in dry THF (80 mL) was dropped under stirring to a cooled suspension of lithium aluminium hydride (1.40 g, 36.6 mMol) in dry THF (150 mL), and the resulting mixture was heated at reflux for 1.5 h. After cooling, the mixture was cautiously quenched with water (50 mL), the solvent was evaporated and the aqueous phase was extracted with CHCl s (3x50 mL). The organic layers were combined, washed with brine (100 mL), dried and evaporated to give an oily residue pure on TLC (AI 20slAcOEt).
General procedure for the preparation of derivatives 10,20
Method A -A suspension of 9 or 19 (18.3 mMol) and activated manganese dioxide (31.10 g, 366.0 mMol) in CH 2CI 2 (100 mL) was stirred at room temperature for 2 h. The suspension was filtered and the solvent was evaporated to give 10 or 20 as a pale yellow oil pure on TLC (Si0 2/AcOEtCHCls 1:2). Method B -Under dry nitrogen, 7-oxo-7-(5-methyl-2thienyl)heptanoic acid 8 (1.20 g, 4.9 mMol) was dissolved in dry THF(100 mL) and the solution was cooled to -15 DC and treated dropwise with a 1M boranelTHF solution (5.0 mL). The resulting mixture was stirred at room temperature for 2 h, then cautiously quenched with water (50 mL) and the solvent was evaporated. The aqueous phase was extracted with CHCl s (3x50 mL), the collected organic layers were washed with 2N KOH (2x100 mL) and then with brine (2x100 mL). After drying, the solvent was evaporated to furnish 10 as a crude residue, which was purified by column chromatography.
1-(5-Methyl-2-thienyl)-7-chloro-1-heptanone 15
Triphenylphosphine (1.20 g, 4.6 mMol) was added to a stirred solution of 1-(5-methyl-2-thienyl)-7-hydroxy-1-heptanone 10 (0.70 g, 3.1 mMol) in dry carbon tetrachloride (100 mL). After exothermic reaction stopped, the mixture was refluxed for 18 h, then cooled and the solvent was removed to give a residue, which was chromatographed to furnish pure 15.
(8)-1 O-Camphorsulfonic acid (R)-4-(4,5-dihydro-4methyl-2-oxazolyl)phenol ester 17
Triethylamine (28.3 mg, 0.04 mL, 0.28 mMol) and (S)-10-campharsulfonyl chloride (70.8 mg, 0.28 mMol) were added to a stirred solution of 11c (50.0 mg, 0.28 mMol) in dry THF (30 mL) and the resulting mixture was stirred at room temperature for 0.5 h. After treatment with water (50 mL) and extraction with diethyl ether (3x15 mL), the collected organic extracts were washed with 2N HCI (10 mL), 2N KOH (10 mL) and brine (10 mL), then dried and evaporated to give 17 as a white solid pure on TLC (Si0 2/AcOEtCHCls 1:2).
Materials and Experimental Proceedures: Virology
HeLa Ohio or VERO cells were grown at 37"C in a 5% CO2 atmosphere in Dulbecco's modified medium (D-MEM) supplemented with 10% fetal calf serum (FCS), 100 U mL-1 penicillin G, and 100 Ilg mL-1 streptomycin. Cultures were checked periodically for the absence of mycoplasma contamination with a MicoTect kit (Gibco). Compounds were solubilized in DMSO as 200x stock solutions and then were serially diluted in maintenance medium to achieve the required final concentrations. Antipicornavirus assays were based on inhibition of virus-induced cytopathogenicity. Briefly, 40.000 HeLa or VERO cells were seeded in each well of flat-bottomed microtitre trays in 50 ul, of D-MEM containing 2% fetal calf serum, 30 mM MgCI 2 , and 15 Ilg mL-1 DEAE-dextran. The cells were then allowed to form a subconfluent monolayer by incubating overnight at 37 DC in a humidified incubator under a 5% CO 2 atmosphere. 50 ul, of maintenance medium containing various concentrations 'of test compounds were then added, followed by 20 ul, of an HRV or polio and coxsackie suspension calibrated to produce complete cytopathic effect within 72 h after infection [400-4000 infectious virus particles (PFU) monolayer"], Following incubation at 33 DC or 37 DC, viability of the HeLa or VERO cells was determined by the 3-(4,5-dimethylthiazol-2-yl)-2,5diphenyltetrazolium bromide (MTT) method.
Cytotoxicity of test compounds was evaluated in parallel with their antiviral activity. It was based on the viability of mockinfected cells, as monitored by the MTT method after 72 h incubation at 37 DC.
